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Introduction: Gliosarcoma is a very rare primary mixed tumor in the central nervous system,
with a biphasic pattern consisting of glial and malignant mesenchymal elements. Its onset
is between the fourth and sixth decade of life, and it has a male/female ratio of 1.8/1. Here
we present two cases of Gliosarcoma treated in our department.Keywords:
Gliosarcoma
Two cases report
Discussion: The monoclonal or biclonal origin of its biphasic nature is still subject to debate;
hence the importance of its diagnosis and histogenesis.
Results: Standard treatment consists in surgical resection of the tumor followed in some
cases by external radiotherapy and chemotherapy.
© 2010 Greater Poland Cancer Centre, Poland. Published by Elsevier Urban & Partner Sp.
z.o.o. All rights reserved
anterior portion of the uncus with a mass effect shifting the
midline.
A left-side frontotemporal craniotomy and complete
macroscopic resection were performed. Histological1. Introduction
Gliosarcoma (GS) is a very rare primary mixed tumor in the
central nervous system, with a biphasic pattern consisting of
glial (anaplastic astrocytes) and malignant mesenchymal ele-
ments. Its onset is between the fourth and sixth decade of
life, and it has a male/female ratio of 1.8/1. The monoclonal or
biclonal origin of its biphasic nature is still subject to debate;
hence the importance of its diagnosis and histogenesis. Treat-
ment consists in surgical resection of the tumor followed by
external radiotherapy, and chemotherapy in some cases. Here
we present two cases of GS treated in our department.∗ Corresponding author. Tel.: +34 935656023.
E-mail address: jpardom@hgc.es (J. Pardo).
1507-1367/$ – see front matter © 2010 Greater Poland Cancer Centre, Poland
doi:10.1016/j.rpor.2010.05.0032. Clinical cases
2.1. Case #1
A 58-year-old male consulted for left-sided hemicranial
cephalea, long-standing dizziness and instability, downfall
and expressive aphasia. BrainMRI showed amultinodular cys-
tic lesion in the left temporal region measuring 5 cm, and an. Published by Elsevier Urban & Partner Sp. z.o.o. All rights reserved






































gFig. 1 – MRI-hy
xamination showed a biphasic pattern tumor, with unusual
usiform areas in a collagenized stroma, and areas of glial cell
roliferation in a ﬁbrillar matrix with vascular proliferation
nd necrosis, which were positive for reticulin staining.
mmunohistochemistry showed glial protein expression
n the glial component and positive vimentin in both. A
ost-operative period passed without complications, bring-
ng a gradual improvement in the language aphasia with
o neurological deﬁcit. Post-operative MRI showed some
ost-operative changes, a cystic cavity with mild edema, and
nlargement of the left temporal horn.
The patient was then referred to our department and
nderwent a post-operative radiotherapy treatment using an
socentric ﬁeld technique, with 6MV photons, receiving a total
ose of 60Gy in 30 fractions (2Gyper fraction). AdjuvantTemo-
olamide therapy was administered. The treatments were
ollowed by a free disease period of 5months. Then the patient
oved to another city and we could not continue his follow-
p.
.2. Case #2
59-year-old male consulted for right-side hemiparesia and
lobal aphasia. Neurological examination revealed no further
eﬁcit. Brain CT revealed lesions in the left frontoparietal
egion and in the paraventricular white matter, which were
nterpreted as an infarction of the middle brain artery. Brain
RI also showed a hyperintense lesion in the frontoparietal
egion mimicking a tumor. Neuronavigator-assisted left fron-
oparietal craniotomy and an extended biopsy of the lesion
ere performed.
Histological examination revealed amalignant brain tumor
ith a biphasic pattern, with glial tissue and a mesenchyma-
ous component. The glial component had characteristics of
lioblastoma, cellular atypia, ischemic necrosis, an increased
itotic rate and expression of ﬁbrillary acidic protein. The
esenchymal component had groups of fusocellular cells.mmunohistochemistry was positive for vimentin and retic-
lin ﬁbers. Inﬁltration of adventitia and a muscular layer on
he wall of a vessel for gliomatosis cells positive for ﬁbrillar
lial protein was revealed.ntense lesion.
Thepatientwas referred to our department,where an adju-
vant three-dimensional conformal radiotherapy treatment
was performed, with 6 and 18MV photons, delivering a total
dose of 60Gy in 30 fractions (2Gy per fraction). The patient
responded well until 8 months later, when there was a sud-
den decline in his general condition, leading to death soon
afterwards.
3. Discussion
Malignant gliomas account for 35–45% of all adult brain
tumors, and approximately 85% are glioblastomas.1 So,
glioblastomas account for 29.7–38.2% of all adult brain tumors.
Gliosarcoma constitutes approximately 2% of all glioblas-
toma, and accounts for 0.59–0.76% of all adult brain tumors
(Figs. 1–3).
GS was described for the ﬁrst time in 1895 by Stroebe2 and
deﬁned as a subtype of glioblastoma by Feigin and Gross3 in
1955 and Rubinstein4 in 1956.
GS is currently deﬁned as a morphological variant of
glioblastoma multiforme, which accounts for between 1.8 and
8% of cases. It typically affects older men, with onset between
the fourth and sixth decades of life and a male/female ratio of
1.8/1, although some cases of infantile gliosarcoma have also
been described.5
It is normally located in the supratentorial region with a
slight preference for the temporal lobes,6 although it can also
affect the frontal, parietal and occipital lobes.7 In some cases,
metastatic extraneural dissemination has been described to
occur via the blood to lung, bone and lymphatic ganglion
tissues, as well as intraaxial, brainstem and spinal cord
dissemination.6,8,9 It is clinically and radiologically indistin-
guishable from glioblastoma multiforme.10
Patients’ clinical proﬁles may include a syndrome of
endocranial hypertension such as cephalea, dizziness, vom-
iting, papilledema, convulsions and motor deﬁcit. CT shows
a well-deﬁned hyperdense lesion with a marked perilesional
edema, necrotic areas and a mass effect. MRI showed a hyper-
intense lesion in T1. An isointense lesion is visible in the T2
sequence.11,12
100 reports of practical oncology and radiotherapy 1 5 ( 2 0 1 0 ) 98–102Fig. 2 – Histology: mesenchymal and glial comp
Fig. 3 – Radiotherapy plan. Inner magenta line: surgical bed; blu
(PTV2); outer magenta line: PTV1 (surgical bed +20mm) (CTV1) +onents. HE 400×. IHC, GFAP, and vimentin.
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Histologically it is a mixed tumor consisting of two com-
onents which are mesenchymal and glial. The sarcomatous
esenchymal tissue presents spindle-shaped cells; it may
resent a ﬁshbone architecture typical of the ﬁbrosarco-
as that are either distinguished or forming disorganized
ascicles and pleomorphic cells. GS has been described to
how mesenchymal differentiation other than ﬁbrosarcoma,
s occurs in epilethial differentiation, myoﬁbroblasts, car-
ilage, bone, angiosarcoma, smooth muscle and striated
uscle.13–19 The glial component is astrocytic and mimics
lioblastoma.
Reticulin stains demonstrate a single-cell pattern of retic-
lin positivity, which correlates with basal lamina deposition
ltrastructurally, whereas the pure glial areas of the same
umors are reticulin negatives.20
The immunohistochemical ﬁndings enable to identify the
lial component of the glial ﬁbrillary acidic protein (GFAP) and
heprotein S-100.Among the epithelial components are cytok-
ratins and immunoreactivity for p53 and, occasionally, actin,
f there is a muscular component.21
There is some controversy regarding the pathogenesis of
liosarcoma. Someauthorsmaintain that there occurs a sarco-
otose transformation of the endolethial glioblastoma cells,
hile others suggest that the sarcomotose component orig-
nates in the smooth muscle cells of adventitia of vessels
r pericytes, ﬁbroblasts, and undistinguished mesenchymal
ells.4,10,22
More recent research suggests a monoclonal origin for the
wo components with a phenotype dedifferentiation, based
n the identical genetic alterations in the two components
f the tumor, i.e. the presence of p53 and PTEn mutations,
16 deletions and a coampliﬁcation of MDM2 and CDK4.22,23
he predominance of sarcomatosis is associated with a better
rognosis and a longer period of time without recurrence.24
The morphological differential diagnosis should include
lioblastoma, glioﬁbroma and other sarcomas. Occasional
lioblastomas may show considerable connective tissue reac-
ion which may be caused by meningeal invasion by tumor or
rganization of zones of necrosis, or as a response to marked
icrovascular proliferation. The lack of the mosaic pattern
lternating areas of glioma and sarcoma should assist in dif-
erential diagnosis 20,25.
Glioﬁbroma is a much less common entity which is also a
ixture of astrocytic and mesenchymal elements, mostly in
spindle cell pattern. It usually affects children and is more
ommon in females. Several of the reported examples have
een in the spinal cord. The tumor cells often have some
urrounding reticulin staining and the basal lamina seen by
lectron microscopy. It is a biphasic tumor composed of a glial
omponent that ranges from low-grade to high-grade differ-
ntiation, but the stromal component is a non-sarcomatous
ype. The prognostic of glioﬁbromas is usually favourable with
ccasionally aggressive comportment.26,27
Primary sarcomas of the CNS are extraordinarily rare.
etastatic sarcomas are more common, although rare. In
ither case there is no double glial and sarcomatous expres-
ion, which deﬁnes gliosarcoma.25,27
The prognosis for GS is generally poor, with an average sur-
ival of less than 8–24 months from the onset of symptoms.6
he brain edema with increase in intracranial pressure andtherapy 1 5 ( 2 0 1 0 ) 98–102 101
herniation of the temporal lobe are the immediate causes of
death.
The standard treatment is the same as that administered
for glioblastomas, namely surgical resection of the tumor
and followed in some cases by external radiotherapy and
chemotherapy.28 The mean overall survival of patients receiv-
ing radiotherapy is longer (10.6 months) than for those treated
only with surgery (6.2 months).29
Radiotherapy should begin 4 weeks after a surgery. Identi-
ﬁcation of the clinical target volume (CTV) is recommended,
using post-surgical MR with gadolinium in a T1 sequence.
The dominant pattern of failure of glioblastoma is within
the contrast enhancing lesions seen on CT or MRI, up to 80%
in the ﬁeld of tumor and up to 22% in the ﬁrst centimeter
adjacent to surgical bed.30 These studies have been done by
correlating information from CT and MRI studies of patho-
logical tissue samples from stereotactic brain biopsies made
among patients initially untreated, and serial samples of brain
during surgery or autopsy The intent of the current study is
to focus treatment exclusively at the enhancing residual mass
following surgery.
More recent studies31,32 of conformal radiotherapy deﬁne
two or three-volume targets in relation to the contrast
enhancement deﬁned as macroscopic residual tumor volume
to achieve higher dose. In volume corresponding to the GTV
plus a small margin of 0.5 cm, the rate of relapse observed was
as high as 78–89%. This zone corresponds to the target volume
estimate that receives the highest dose. Beyond a distance of
2.5 cm from GTV the relapse rate is low, 3–9%. All these studies
conﬁrm that themainmode of relapse is local, in a deﬁned vol-
ume around the GTV with a margin of 2–3 cm. The RTOG trials
98-03 and 08-25 recommended volumes are: CTV1= surgical
bed and/or residual tumor +20–25mm, CTV2= surgical bed
and/or residual tumor +5mm. The planning target volume
(PTV) is an additional margin of 3–5mm, depending upon
localization method and reproducibility, at each center.
Thanks to breakthroughs in neuroimaging (CT, MRI and
PET), computer dosimetry and conformal radiation tech-
niques such as 3D-CRT, it is possible to administer uniform
doses in target volumes while avoiding the effect on normal
tissues.33,34 Doses of over 60Gy and boost on the surgical bed
do not appear to inﬂuence survival. Recent studies on dose
escalation with radiosurgery, an interstitial implant, or IMRT
have not shown a signiﬁcant increase in survival. The stud-
ies of dose hyperfractionation and intraoperative radiotherapy
are controversial.35,36,37
GS is a chemoresistant tumor, but the literature suggests
that the use of Temozolamide at the same time as radiother-
apy as a ﬁrst-line treatment at doses of 75mg/m2 per day 1h
before radiotherapy and at weekends, and after the radiother-
apy treatment is concluded, as an adjuvant treatment in doses
of 150mg/m2 for 5 cycles, slightly increases survival.33
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